# IVVD catalysts: Invivyd, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ivvd/catalysts

> Invivyd, Inc. (IVVD) has 2 upcoming catalysts. The next is the VYD2311 primary completion, June 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Invivyd, Inc. |
| Ticker | IVVD (Nasdaq) |
| SEC CIK | 1832038 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/ivvd |

## Cash runway

Cash $160.1M as of 2026-06-30; quarterly burn $43.0M; about 11.2 months of runway at that rate (XBRL company facts, accession 0001193125-26-349215).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q4 2024 | [VYD2311 interim data readout](https://sec-api.dev/pdufa/vyd2311) | IVVD |  | scheduled | "Next generation molecule VYD2311 first-in-human clinical trial dosing began in August 2024 with anticipated preliminary data readout late Q4 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312524257993/d894288dex991.htm)) |
| November 14, 2024 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312524257993/d894288dex991.htm)) |
| February 3, 2025 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000095017025012018/ivvd-ex99_1.htm)) |
| March 20, 2025 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000095017025042331/ivvd-ex99_1.htm)) |
| May 15, 2025 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312525120261/d66861dex991.htm)) |
| August 14, 2025 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312525180890/d936404dex991.htm)) |
| November 6, 2025 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312525268057/d81968dex991.htm)) |
| Dec 2025 | [VYD2311 trial start](https://sec-api.dev/pdufa/vyd2311) | IVVD |  | completed | "In December 2025, the Company initiated DECLARATION, which is a Phase 3 randomized, triple-blind, placebo-controlled clinical trial to evaluate VYD2311 safety and efficacy in prevention of symptomatic, RT-PCR-confirmed COVID-19 at three months, with either a single dose or monthly doses of VYD2311, each administered via intramuscular injection, compared to placebo." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1832038/000119312526349215/ivvd-20260630.htm)) |
| March 5, 2026 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092528/d118119dex991.htm)) |
| mid-2026 | [VYD2311 trial start](https://sec-api.dev/pdufa/vyd2311) | IVVD |  | scheduled | "Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092528/d118119dex991.htm)) |
| May 14, 2026 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/d120795dex991.htm)) |
| Jun 2026 | [VYD2311 trial start](https://sec-api.dev/pdufa/vyd2311) | IVVD |  | completed | "LIBERTY: In June 2026, Invivyd announced first participants dosed and completion of enrollment in LIBERTY, a Phase 3 clinical trial to evaluate the safety and tolerability of VYD2311 antibody versus mRNA COVID vaccine and to characterize the safety and immunology of antibody and mRNA vaccine co-administration." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-ex99_1.htm)) |
| Q3 2026 | [VYD2311 topline data readout](https://sec-api.dev/pdufa/vyd2311) | IVVD | COVID-19 | scheduled | "Operating expense increase quarter-over-quarter primarily attributable to DECLARATION pivotal program costs for VYD2311 for which top-line data is anticipated in Q3 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/d120795dex991.htm)) |
| Q3 2026 | [PEMGARDA® (pemivibart) topline data readout](https://sec-api.dev/pdufa/pemivibart) | IVVD |  | scheduled | "Financial UpdateQ1 2026 PEMGARDA® net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million Operating expense increase quarter-over-quarter primarily attributable to DECLARATION pivotal program costs for VYD2311 for which topline data is anticipated in Q3 2026 March 2026 ending cash and cash equivalents of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/d120795dex992.htm)) |
| Q3 2026 | [Invivyd, Inc. topline data readout](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | scheduled | "Depending on recruitment rates, top-line results are now expected to shift from "mid-year" 2026 (defined as either 2nd or 3rd quarter), to in the third quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526148865/d147019dex991.htm)) |
| August 2026 | [VYD2311-SD primary completion](https://sec-api.dev/pdufa/vyd2311-sd) | IVVD | COVID-19 | delayed | "NCT07298434 (Study of VYD2311 for the Prevention of COVID-19): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor Invivyd, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07298434)) |
| Aug to Nov 2026 | [VYD2311-SD topline data readout](https://sec-api.dev/pdufa/vyd2311-sd) | IVVD | COVID-19 | scheduled | "NCT07298434 (Study of VYD2311 for the Prevention of COVID-19): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor Invivyd, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07298434)) |
| August 13, 2026 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-ex99_1.htm)) |
| August 15, 2026 | [VYD2311 primary completion](https://sec-api.dev/pdufa/vyd2311) | IVVD | COVID-19 | completed | "NCT07655180 (Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-15 (ACTUAL); Lead Sponsor Invivyd, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07655180)) |
| September 29, 2026 | [VYD2311 topline data readout](https://sec-api.dev/pdufa/vyd2311) | IVVD |  | completed, met | "NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3, randomized, double-blind, active controlled study evaluating the safety and tolerability of (1) VYD2311, Invivyd's investigational COVID-directed monoclonal antibody candidate, (2) mRNA-based COVID-19 vaccine COMIRNATY® (mRNA-based COVID-19 vaccine, COVID-19 mRNA vaccine, or COVID vaccine), and (3) VYD2311 co-administered with mRNA-based COVID-19 vaccine." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526406007/ivvd-ex99_1.htm)) |
| June 2027 | [VYD2311 primary completion](https://sec-api.dev/pdufa/vyd2311) | IVVD | Long COVID; COVID-19 (SARS-CoV-2 Infection); COVID 19 Vaccine | scheduled | "NCT07899346 (Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Invivyd, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07899346)) |
| Jun to Sep 2027 | [VYD2311 topline data readout](https://sec-api.dev/pdufa/vyd2311) | IVVD | Long COVID; COVID-19 (SARS-CoV-2 Infection); COVID 19 Vaccine | scheduled | "NCT07899346 (Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Invivyd, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07899346)) |

## Drugs

- [PEMGARDA® (pemivibart)](https://sec-api.dev/pdufa/pemivibart): 
- [VYD2311](https://sec-api.dev/pdufa/vyd2311): COVID-19, Long COVID
- [VYD2311-SD](https://sec-api.dev/pdufa/vyd2311-sd): COVID-19

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ivvd/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IVVD catalysts: Invivyd, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ivvd/catalysts

```bibtex
@misc{secapidev_companies_ivvd_catalysts_20261116,
  title        = {IVVD catalysts: Invivyd, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ivvd/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ivvd_catalysts_20261116","title":"IVVD catalysts: Invivyd, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ivvd/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
